Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
January 08, 2024 08:00 ET
|
Biora Therapeutics, Inc.
SAD/MAD study to evaluate safety and PK/PD of BT-600 drug-device combination, including concentrations in colon tissue
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
January 02, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Biora's BioJet™ drug delivery platform exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study.
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
December 19, 2023 08:00 ET
|
Biora Therapeutics, Inc.
Biora's latest patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract.
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
December 18, 2023 08:00 ET
|
Biora Therapeutics, Inc.
Transaction results in nearly 60% reduction in net debt and brings $16 million in new capital; demonstrates investor confidence in near-term catalysts.
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
December 11, 2023 08:00 ET
|
Biora Therapeutics, Inc.
Pharma collaborator’s proprietary molecules will be tested with the BioJet platform in animal models.
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
November 30, 2023 16:48 ET
|
Biora Therapeutics, Inc.
BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 13, 2023 16:05 ET
|
Biora Therapeutics, Inc.
NaviCap™ platform advancing toward initiation of phase 1 clinical trial by year end; Pharma collaborations accelerate for the BioJet™ platform
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
November 06, 2023 08:00 ET
|
Biora Therapeutics, Inc.
Biora will report financial results and provide a corporate update for the third quarter on on Monday, November 13, 2023, at 4:30 PM EST / 1:30 PM PST
Biora Therapeutics Submits Updated IND Application for BT-600
October 30, 2023 16:05 ET
|
Biora Therapeutics, Inc.
Update includes supplemental information and provides additional time to complete regulatory review; company expects to remain on track with Ph1 timeline.
Biora Therapeutics to Submit Updated IND Application for BT-600
October 23, 2023 17:30 ET
|
Biora Therapeutics, Inc.
Update to include supplemental information and allow additional time for regulatory review. Biora anticipates remaining on track with ph1 trial timeline.